Investors / Switzerland / Nextech Invest
Nextech Invest
Venture capital · Zurich, Switzerland · Europe
Nextech Invest is a Zurich-based investment firm that backs emerging biotechnology companies worldwide. It focuses on identifying transformative cancer medicines and supports its portfolio through scientific validation and value creation.
Invests inHealthcare & Biotech
In its own wordsbiotechoncologyprecision medicinelife sciencestherapeutics
Your fit with Nextech Invest
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNextech Invest lists 49 checked portfolio companies on its own site and is named in 11 funding rounds, 5 of them as lead. Its most frequent entry is Series B, 40% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 83% of its companies are based in United States. It invests most often alongside RA Capital, Casdin Capital and Boxer Capital.
Counts come from funding rounds that name Nextech Invest, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Nextech Invest's whole history. Rounds on record name 10 companies; its own site lists 49. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundNextech Invest does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 20% |
| Series B | 40% |
| Growth | 40% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 1 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 2 |
| '26 | 8 | 3 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 84th | 50 companies |
| Recent activity | 94th | 9 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 87th | 16% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 16 |
| Casdin Capital | 11 |
| Boxer Capital | 10 |
| Foresite Capital | 10 |
| The Column Group | 6 |
| ARCH Venture Partners | 5 |
| Canaan | 5 |
| Avoro Capital Advisors | 4 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4694%
- No longer answers00%
- Points to another company36%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Nextech Invest head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Nextech Invest| Date | Company | Stage |
|---|---|---|
| 23 Oct 2026 | Series C+ | |
| 7 Oct 2026 | Series B Led | |
| 16 Sept 2026 | Series C+ | |
| 13 Aug 2026 | Series B | |
| 30 Jun 2026 | Series C+ Led | |
| 5 Mar 2026 | Series B | |
| 8 Jan 2026 | Series C+ | |
| 18 Dec 2025 | Series B Led |
Round details for Nextech Invest
Amounts, full round histories and every co-investor in Nextech Invest's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
49 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| A2 Biotherapeutics is developing cell therapies, including CAR T-cell therapies, to treat solid tumors and other diseases. | Healthcare & Biotech | Portfolio page | ||
| Alpha-9 Oncology is a clinical stage radiopharmaceutical company advancing a portfolio of molecules to treat cancer cells | Healthcare & Biotech | Portfolio page | ||
| Airna is developing novel medicines with the potential to deliver functional cures for patients using RNA editing technology. | Healthcare & Biotech | Portfolio page | ||
| Alterome Therapeutics is a clinical-stage precision oncology company that develops therapies for cancer treatments. | Healthcare & Biotech | Portfolio page | ||
| Alumis Inc is focused on immune-mediated disease therapies | Healthcare & Biotech | Portfolio page | ||
| The company is developing a new class of medicines that can interact with previously undruggable targets | Healthcare & Biotech | Portfolio page | ||
| Arrakis Therapeutics creates genetic medicines, specifically RNA-targeted small molecules, to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| ARS Pharmaceuticals develops patient-friendly treatments, including a needle-free epinephrine product called neffy | Healthcare & Biotech | Portfolio page | ||
| Arvinas develops targeted protein degradation therapeutics for serious diseases, particularly in neurology and oncology. | Healthcare & Biotech | Portfolio page | ||
| Atavistik Bio is a clinical-stage biotechnology company developing innovative therapies for patients with serious hematologic diseases. | Healthcare & Biotech | Dec 2025Series B · 2 rounds | Page + round | |
| Attovia Therapeutics is developing next-generation biotherapeutics for immune-mediated diseases. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Portfolio page | ||||
| Portfolio page | ||||
| Boundless Bio develops therapies for patients with intractable oncogene amplified cancers. | Healthcare & Biotech | Portfolio page | ||
| C4 Therapeutics develops a new generation of medicine using targeted protein degradation to treat disease | Healthcare & Biotech | Portfolio page | ||
| Circle Pharma harnesses the power of macrocycles to transform the treatment of cancer. | Healthcare & Biotech | Sept 2026Series C+ | Page + round | |
| Context Therapeutics develops next-generation T cell engaging bispecific antibody therapies for the treatment of solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Cullinan Therapeutics accelerates high-impact therapies in autoimmune diseases and cancer | Healthcare & Biotech | Portfolio page | ||
| Delphia Therapeutics is developing new cancer medicines using a precision medicine approach called activation lethality. | Healthcare & Biotech | Portfolio page |
About this data
site last read 12 Nov 2026- Site
- nextechinvest.com
- Last read
- 12 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 1 Aug 2022
- Companies checked
- 49
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Nextech Invest's profile as data
Pull Nextech Invest's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/nextechinvest.com
# also
GET /v1/firms/nextechinvest.com/portfolio
GET /v1/firms/nextechinvest.com/coinvestors
GET /v1/firms/nextechinvest.com/news